WASHINGTON DC (August 28, 2018) – Statement of the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association, and Mexican Association of Generic Medicines on the Announcement U.S.-Mexico Understanding on Biologic Exclusivity
WASHINGTON DC (May 14, 2018) – Imposition of tariffs on generic drugs, biosimilars or their ingredients would have a perverse effect on health care spending in the U.S. Generic medicines generated $253 billion in savings for patients and taxpayers in 2016, and in the last decade the U.S. health care system has saved $1.67 trillion due to the availability of low-cost generics. Savings for the two largest government health care programs, Medicare and Medicaid, totaled $77 billion and $37.9 billion, respectively, in 2016.
AAM believes that all finished pharmaceuticals, pharmaceutical ingredients and active pharmaceutical ingredients (API) should be removed from the annex of products to be subject to additional duties published in USTR’s 301 Notice. Imposing an additional 25 percent tariff on such products will increase the cost of prescription drugs for patients in the United States, taxing their health and well-being, which will cause disproportionate economic harm for consumers and is unlikely to result in the desired changes to China's practices.
WASHINGTON, DC (April 4) –
“The Association for Accessible Medicines (AAM) and our members who manufacture generic and biosimilar medicines are aligned with the president’s goal of lowering prescription drug prices for patients in the U.S.
Association for Accessible Medicines is calling on Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.
To this end, we recommend these seven policy solutions:
WASHINGTON, DC (September 19, 2017) – The Association for Accessible Medicines, the Canadian Generic Pharmaceutical Association and the Mexican Association of Generic Medicines are urging their three governments not to raise drug prices for patients by extending monopolies for brand name medicines and biologics under a renegotiated North American Trade Agreement (NAFTA).